Welcome to DERAMAXX® (deracoxib)
Novartis Animal Health US, Inc. is committed to helping pets live long, rewarding lives. They know your dog is more than just a pet—he’s a full-fledged member of your family. So when he feels pain caused by canine arthritis, you naturally want to do everything you can to help control that pain; especially when the pain is every day.
Now there is a solution. We can help control chronic osteoarthritis (OA) pain in your dog with DERAMAXX. It’s a breakthrough medication proven safe enough to use every day. And your dog will love it because this tasty, beefy-flavored tablet is chewable just like his favorite treat.
Osteoarthritis—Dogs Feel Pain Like You Do
Osteoarthritis is a degenerative disease that affects a dog’s joints. It is the most common cause of chronic pain in dogs. The fact is, one out of five adult dogs suffers from arthritis severe enough to make it difficult for him to jump, climb stairs, even get in and out of the car. But just like thousands of pet owners who already give DERAMAXX to their dogs, you can help control your dog’s OA pain so he gets relief all day, every day.
EVERY DAY. BECAUSE THE PAIN IS EVERY DAY.
As with all drugs in this class, side effects involving the digestive system, kidneys or liver may occur. These are normally mild, but may be serious. Pet owners should discontinue therapy and contact their veterinarian immediately if side effects occur. Evaluation for preexisting conditions and regular monitoring are recommended for pets on any medication, including Deramaxx. Use with other NSAIDs or corticosteroids should be avoided.
Deramaxx Rx, Chew Tabs (25mg 100mg) DERAMAXX? Rx Novartis (deracoxib) Chewable tablets For Oral Use In Dogs Only Description: DERAMAXX (deracoxib) tablets are a non-narcotic, non-steroidal anti-inflammatory drug of the coxib class. DERAMAXX tablets are round, biconvex, chewable tablets that contain deracoxib formulated with beefy flavoring. The molecular weight of deracoxib is 397.38. The empirical formula is C17-H14-F3-N3-O3-S. Deracoxib is 4-[5-(3-difluoro-4-methoxyphenyl)-(difluoromethyl)-1H-pyrazole-1-yl] benzenesulfonamide, and can be termed a diaryl substituted pyrazole. The structural formula is: Clinical Pharmacology Mode of Action: DERAMAXX tablets are a member of the coxib class of non-narcotic, non-steroidal, cyclooxygenase-inhibiting anti-inflammatory drugs for the control of postoperative pain and inflammation associated with orthopedic surgery and for the control of pain and inflammation associated with osteoarthritis in dogs. Data indicate that deracoxib inhibits the production of PGE1 and 6-keto PGF1 by its inhibitory effects on prostaglandin biosynthesis1. Deracoxib inhibited COX-2 mediated PGE2 production in LPS-stimulated human whole blood2. Cyclooxygenase-1 (COX-1) is the enzyme responsible for facilitating constitutive physiological processes (e.g., platelet aggregation, gastric mucosal protection, renal perfusion).3 Cyclooxygenase-2 (COX-2) is responsible for the synthesis of inflammatory mediators.4 Both COX isoforms are constituitively expressed in the canine kidney.5 At doses of 2-4 mg/kg/day, DERAMAXX tablets do not inhibit COX-1 based on in vitro studies using cloned canine cyclooxygenase6. The clinical relevance of this in vitro data has not been shown. Although the plasma terminal elimination half-life for DERAMAXX tablets is approximately 3 hours, a longer duration of clinical effectiveness is observed. Summary pharmacokinetics of DERAMAXX tablets are listed in table 1. table 1: Pharmacokinetics of Deracoxib Parameter Value Tmax a 2 hours Oral Bioavailability (F) a > 90% at 2 mg/kg Terminal elimination half-life b 3 hours at 2-3 mg/kg 19 hours at 20 mg/kg Systemic Clearance b ~ 5 ml/kg/min at 2 mg/kg ~ 1.7 ml/kg/min at 20 mg/kg Volume of Distribution c ~ 1.5 L/kg Protein binding d > 90% a Values obtained following a single 2.35 mg/kg dose b Estimates following IV administration of deracoxib as an aqueous solution c Based upon a dose of 2 mg/kg of deracoxib d Based upon in vitro plasma concentrations of 0.1, 0.3, 1.0, 3.0, 10.0 ?g/ml Non-linear elimination kinetics are exhibited at doses above 8 mg/kg/day, at which competitive inhibition of constitutive COX-1 may occur. Deracoxib is not excreted as parent drug in the urine. The major route of elimination of deracoxib is by hepatic biotransformation producing four major metabolites, two of which are characterized as products of oxidation and o-demethylation. The majority of deracoxib is excreted in feces as parent drug or metabolite. Large intersubject variability was observed in drug metabolite profiles of urine and feces. No statistically significant differences between genders were observed. Indications and Usage: Osteoarthritis Pain and Inflammation: DERAMAXX Chewable tablets are indicated for the control of pain and inflammation associated with osteoarthritis in dogs.